2020
Blood Conservation Strategy at Time of Left Ventricular Assist Device Placement Improves Survival
Stawiarski K, Agboola O, Park J, Mangi A, Geirsson A, Lee F, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Testani J, Chen M, McCloskey G, Bonde P. Blood Conservation Strategy at Time of Left Ventricular Assist Device Placement Improves Survival. The Journal Of Heart And Lung Transplantation 2020, 39: s151. DOI: 10.1016/j.healun.2020.01.1086.Peer-Reviewed Original ResearchVentricular assist device placementBlood conservationLeft ventricular assist device placementBCS groupDevice placementAnti-platelet useLarger ventricular sizeLiberal transfusion strategyStandardized transfusion protocolTime of LVADLength of hospitalBlood conservation strategiesUnits of PRBCsLiberal groupCirculatory support devicesDevice use ratesExcessive transfusionICU stayTransfusion protocolCommon complicationHeart failureLVAD patientsTransfusion strategyTransfusion triggerSingle center
2006
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Research And Treatment 2006, 104: 341-349. PMID: 17051423, DOI: 10.1007/s10549-006-9413-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionEnd of chemotherapyEquilibrium radionuclide angiographyBreast cancerAdjuvant therapySequential doxorubicinCardiac functionIpsilateral axillary lymph nodesHigh-risk breast cancerRisk breast cancerClinical heart failureInitiation of chemotherapyAxillary lymph nodesVentricular ejection fractionEnd of therapyLong-term cardiotoxicityMedian absolute changeEligible patientsFilgrastim supportLate cardiotoxicityAxillary nodesAsymptomatic declineEjection fractionHeart failureLymph nodes
2004
Comparative costs of home positive inotropic infusion versus in-hospital care in patients awaiting cardiac transplantation
Upadya SP, Sedrakyan A, Saldarriaga C, Nystrom K, Bozzo J, Lee FA, Katz SD. Comparative costs of home positive inotropic infusion versus in-hospital care in patients awaiting cardiac transplantation. Journal Of Cardiac Failure 2004, 10: 384-389. PMID: 15470648, DOI: 10.1016/j.cardfail.2004.02.004.Peer-Reviewed Original ResearchConceptsCardiac transplantationAutomatic implantable cardioverter defibrillatorInotropic therapyOutpatient strategiesAICD implantationHospital careEnd-stage heart failurePositive inotropic supportImplantable cardioverter defibrillatorDecision analysis modelInotropic supportHospital dischargeHeart failureInotropic infusionUnited NetworkHospital treatmentHospital costsCardioverter defibrillatorSuccessful bridgePatientsTransplantationHospital monitoringOutpatientsDaily costTherapyHome continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure
Upadya S, Lee FA, Saldarriaga C, Verma S, Sedrakyan A, Nystrom K, Katz SD. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. The Journal Of Heart And Lung Transplantation 2004, 23: 466-472. PMID: 15063407, DOI: 10.1016/s1053-2498(03)00203-1.Peer-Reviewed Original ResearchConceptsPositive inotropic therapyInotropic therapyCardiac transplantationFunctional capacityDecreased health care costsEnd-stage heart failureImplantable cardioverter-defibrillator dischargeHome therapy patientsStatus 1B patientsInitiation of therapyStable clinical statusNumber of hospitalizationsPre-treatment baselineImplantable cardioverter defibrillatorHealth care costsActuarial survivalInotropic treatmentRenal functionConsecutive patientsHeart failureClinical statusHemodynamic monitoringHome infusionInotropic infusionUnited Network
2003
Sustained hemodynamic benefit during long-term positive inotropic infusion in patients with advanced heart failure
Upadya S, Lee F, Saldarriaga C, Nystrom K, Katz S. Sustained hemodynamic benefit during long-term positive inotropic infusion in patients with advanced heart failure. Journal Of The American College Of Cardiology 2003, 41: 163-164. DOI: 10.1016/s0735-1097(03)81804-1.Peer-Reviewed Original Research
2000
The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function
Rose M, Lee F, Gollerkeri A, D'Andrea E, Psyrri A, Bdolah-Abram T, Burtness B. The feasibility of high-dose chemotherapy in breast cancer patients with impaired left ventricular function. Bone Marrow Transplantation 2000, 26: 133-139. PMID: 10918422, DOI: 10.1038/sj.bmt.1702449.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCombined Modality TherapyCyclophosphamideDoxorubicinFemaleFollow-Up StudiesHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMiddle AgedNeutropeniaPaclitaxelStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsLeft ventricular ejection fractionHigh-dose chemotherapyBreast cancer patientsMean absolute decreaseCancer patientsAbsolute decreaseLV functionCell rescueImpaired left ventricular functionHigh-dose thiotepaImpaired LV functionHigh-dose melphalanStem cell rescueSymptomatic heart failureCourses of chemotherapyVentricular ejection fractionLeft ventricular functionSequential paclitaxelMetastatic diseaseCardiac deathCardiac symptomsEjection fractionHeart failureVentricular functionCardiac toxicity
1995
Medical Therapy and Prognosis in Chronic Heart Failure Lessons from Clinical Trials
Ramahi T, Lee F. Medical Therapy and Prognosis in Chronic Heart Failure Lessons from Clinical Trials. Cardiology Clinics 1995, 13: 5-26. PMID: 7796432, DOI: 10.1016/s0733-8651(18)30058-4.Peer-Reviewed Original ResearchConceptsChronic heart failureLeft ventricular dysfunctionIntermediate-term improvementVentricular dysfunctionClinical trialsHeart failureLong-term improvementHemodynamic improvementLong-term effectsFunctional capacityShort-term hemodynamic improvementSystolic left ventricular dysfunctionChronic left ventricular dysfunctionACE inhibitor therapyRole of diureticsImmediate symptomatic reliefMajor clinical trialsSympathetic nervous systemMarker of prognosisGoal of therapyPure vasodilationAldosterone systemDirect vasodilatorAcute stabilizationPharmacologic therapy